Loading…
IRADIMED CORPORATION is projected to rise to $133.87 by 2027, a +38% move from its current price of $97.20. IRMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $95.72 | $97.26 | $98.83 | +0.06% |
| Jul 15 | $95.15 | $97.33 | $99.55 | +0.13% |
| Jul 16 | $94.73 | $97.39 | $100.12 | +0.19% |
| Jul 17 | $94.39 | $97.45 | $100.62 | +0.26% |
| Jul 18 | $94.09 | $97.51 | $101.06 | +0.32% |
| Jul 19 | $93.83 | $97.58 | $101.47 | +0.39% |
| Jul 20 | $93.60 | $97.64 | $101.86 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $93.60 | $97.64 | $101.86 | +0.45% |
| Week 2 | $92.39 | $98.08 | $104.12 | +0.91% |
| Week 3 | $91.57 | $98.52 | $106.01 | +1.36% |
| Week 4 | $90.94 | $98.97 | $107.70 | +1.82% |
| Week 5 | $90.45 | $99.42 | $109.27 | +2.28% |
| Week 6 | $90.04 | $99.87 | $110.76 | +2.74% |
| Week 7 | $89.70 | $100.32 | $112.19 | +3.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IRADIMED CORPORATION develops, manufactures, markets, and distributes MRI compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
IRADIMED CORPORATION is a healthcare stock with the symbol IRMD. The current price is $100.97 and it sits in a market position of $1.29B in market capitalization with a rank of 2306.
The forecast suggests a rising price path beyond 2026, with a 2026 average of $100.97 and a broad 30-day range, before higher averages materialize in following years.
For 2027 through 2050, the forecast shows a clear bullish trajectory, with rising average prices and meaningful potential upside, including a 2040 average of $579.19 and a 2050 average of $1,120.53. These figures imply substantial longer-term upside, albeit with inherent uncertainty and risk.
A major floor 14.2% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 12.0% above — clearing it would confirm fresh momentum.
Key IRMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $98.82 | Sell | $97.91 | Sell |
| MA 10 | $97.67 | Sell | $97.39 | Sell |
| MA 20 | $95.25 | Buy | $95.95 | Buy |
| MA 50 | $91.65 | Buy | $94.03 | Buy |
| MA 100 | $94.57 | Buy | $93.23 | Buy |
| MA 200 | $91.76 | Buy | $88.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.97 | Neutral |
| Stoch RSI (14) | 23.85 | Neutral |
| CCI (20) | 46.96 | Neutral |
| Williams %R (14) | -48.07 | Info |
| MACD (12,26,9) | 0.16 | Buy |
| ROC (12) | 5.24 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 51.93 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 4.57 | Buy |
| Ultimate (7,14,28) | 57.55 | Neutral |
| Momentum (10) | 3.33 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 97.76 | Sell |
| ADX (14) | 16.90 | Neutral |
| ATR (14) | 1.56 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 suggesting strong upside momentum.
The stock’s price is aligned near a resistance level of $100.97, while SMA50 sits at $90.60 and SMA200 at $91.07, giving a positive near-term trend context. A support level is cited at $89.86.
Over the past 30 days, the trading range has spanned from a low of $91.68 to a high of $111.20, indicating notable volatility within the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $83.44 | $97.20 | $134.71 | 0% | Neutral | |
| $109.64 | $133.87 | $170.88 | +38% | Bullish | |
| $128.48 | $159.82 | $209.53 | +64% | Bullish | |
| $139.80 | $176.58 | $236.44 | +82% | Bullish | |
| $152.54 | $195.28 | $266.19 | +101% | Bullish | |
| $157.28 | $203.80 | $282.19 | +110% | Bullish | |
| $167.21 | $219.12 | $307.72 | +125% | Bullish | |
| $209.23 | $277.08 | $394.15 | +185% | Bullish | |
| $233.11 | $311.76 | $448.79 | +221% | Bullish | |
| $244.22 | $329.72 | $479.93 | +239% | Bullish | |
| $354.46 | $499.14 | $761.36 | +414% | Bullish | |
| $624.96 | $943.84 | $1,543.24 | +871% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $83.44 | $97.20 | $113.83 | +0.00% |
| August 2026 | $84.09 | $98.42 | $117.69 | +1.26% |
| September 2026 | $87.64 | $103.08 | $124.23 | +4.73% |
| October 2026 | $88.67 | $104.72 | $127.04 | +1.59% |
| November 2026 | $89.06 | $105.54 | $128.74 | +0.79% |
| December 2026 | $92.42 | $109.88 | $134.71 | +4.11% |
Click any year to see its month-by-month IRMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
IRADIMED CORPORATION's 2026 outlook centres on $97.20, within a $83.44 to $134.71 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, IRMD could reach as high as $170.88, with a base case around $133.87 and support toward $109.64 — roughly +38% from $97.20. Momentum favours further upside here.
Expect IRMD to range from $128.48 to $209.53 through 2028. The $159.82 average target implies a +64% move from current prices. That is up +19% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The IRMD price prediction for 2029 points to an average of $176.58 (low $139.80, high $236.44) — a potential gain of +82% on today's $97.20. Momentum favours further upside here.
In 2030, IRMD is projected to trade between $152.54 and $266.19, averaging $195.28 — a potential gain of +101% from today's $97.20. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
IRADIMED CORPORATION's 2031 outlook centres on $203.80, within a $157.28 to $282.19 range. That is up +4% on the projected 2030 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2032, IRMD could reach as high as $307.72, with a base case around $219.12 and support toward $167.21 — roughly +125% from $97.20. Buyers look set to stay in control over this stretch.
Expect IRMD to range from $209.23 to $394.15 through 2033. The $277.08 average target implies a +185% move from current prices. That is up +26% on the projected 2032 average. Momentum favours further upside here.
The IRMD price prediction for 2034 points to an average of $311.76 (low $233.11, high $448.79) — a potential gain of +221% on today's $97.20. Buyers look set to stay in control over this stretch.
In 2035, IRMD is projected to trade between $244.22 and $479.93, averaging $329.72 — a potential gain of +239% from today's $97.20. That is up +6% on the projected 2034 average. Momentum favours further upside here.
IRADIMED CORPORATION's 2040 outlook centres on $499.14, within a $354.46 to $761.36 range. That is up +51% on the projected 2035 average. That marks a +414% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, IRMD could reach as high as $1,543.24, with a base case around $943.84 and support toward $624.96 — roughly +871% from $97.20. Momentum favours further upside here.
Investing $1,000 in IRMD today (≈ 10.288066 IRMD) could be worth
$9,710.24
+$8,710.24 (+871%) by 2050 · US Dollar
Based on the average projected IRMD price of $943.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRMDwould be worth at today's price.
$1,000 invested in IRMD on Jul 10, 2025 (≈ 16.815201 IRMD) would be worth
$1,634.44
+$634.44 (+63.4%) today · 1.63× · US Dollar
Based on a IRMD entry price of $59.47 vs. today's $97.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $100.97 | $962.66 | -3.7% |
| 1 month ago | $96 | $1,012.5 | +1.2% |
| 3 months ago | $93.4 | $1,040.69 | +4.1% |
| 6 months ago | $97.9 | $992.85 | -0.7% |
| 1 year ago | $59.47 | $1,634.44 | +63.4% |
| All time (5.0y) ago | $36.99 | $2,627.74 | +162.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRMD forecast.
Our base-case forecast reaches $190.00 around 2030.
Implied market cap at $190.00: $2.43B
The multi-year forecast begins in 2026 with a min of $83.44, an avg of $100.97, and a max of $143.16, offering an ROI of 0 and a neutral sentiment.
From 2027 onward, the outlook strengthens toward a bullish stance: 2027 avg $141.88 (ROI 40.5), 2028 avg $171.90 (ROI 70.3), 2029 avg $193.10 (ROI 91.3), and 2030 avg $211.43 (ROI 109.4).
The trajectory continues to 2040, where the forecast shows avg $579.19 (ROI 473.6) and bullish sentiment, and reaches 2050 with avg $1,120.53 (ROI 1009.8) and bullish sentiment.
These projections represent estimates and are not guarantees, affected by market conditions and other risks.
Tap a question to reveal the answer.
According to the forecast, the 2030 average price is $211.43 with a min of $165.10 and a max of $288.32, and an estimated ROI of 109.4% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $141.88 (ROI 40.5), 2028 avg $171.90 (ROI 70.3), 2029 avg $193.10 (ROI 91.3), and 2030 avg $211.43 (ROI 109.4). The longer-range outlook remains bullish through 2040 and 2050, though these are estimates not guarantees.
Yes. The 2033 forecast shows min $234.78, avg $310.99, max $442.53 (sentiment bullish), indicating a path that exceeds $300 by 2033. Earlier years show 2032 max $346.60, confirming feasibility by that period.
$1.29B.
IRADIMED CORPORATION Community Discussion
0Share your IRADIMED CORPORATION price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.